A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder.

Abstract

A total of 431 eligible patients with solitary, primary or recurrent stages Ta and T1 transitional cell carcinoma of the bladder was included in a randomized multicenter trial to compare a single intravesical instillation of 80 mg. epirubicin with water given immediately after resection, with respect to the disease-free interval and recurrence rate. The interval to initial recurrence was significantly better in favor of the epirubicin group. After a mean followup of 2 years it became evident that the recurrence rate after a single epirubicin instillation was decreased by nearly half with the same trend being found in all subgroups examined. Toxicity was mainly restricted to bladder irritation in plus or minus 10% of the cases. Pathology review brought considerable changes in T category from stages T1 to Ta (53%). Changes in grade were less pronounced but nevertheless important.

• Authors: W Oosterlinck, K H Kurth, F Schröder, J Bultinck, B Hammond, R Sylvester
• Journal: The Journal of urology (J Urol) Vol. 149 Issue 4 Pg. 749-52 (Apr 1993) ISSN: 0022-5347 [Print] United States
• PMID: 8455236 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Water
• Epirubicin

Topics

• Administration, Intravesical
• Carcinoma, Transitional Cell (drug therapy, epidemiology, surgery)
• Combined Modality Therapy
• Epirubicin (administration & dosage, therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Male
• Neoplasm Recurrence, Local (epidemiology)
• Prospective Studies
• Time Factors
• Urinary Bladder Neoplasms (drug therapy, epidemiology, surgery)
• Water